5th Anniversary of GHIT Fund | Global Health Innovative Technology Fund

“Health is essential to people's fundamental
happiness and a foundation of
prosperous countries.”

Dr. Naoko Yamamoto

Assistant Minister for Global Health
Minister's Secretariat
Ministry of Health, Labour and Welfare

STAKEHOLDER INTERVIEWS

“Japan really was a
logical choice,
but was difficult to approach
as an outsider.”

Dr. David Reddy

Medicines for Malaria Venture (MMV) CEO

STAKEHOLDER INTERVIEWS

“Japan has a vibrant pharmaceutical industry,
which will continue to push on research.”

Mr. Christophe Weber

Representative Director, President and CEO
Takeda Pharmaceutical Company Limited

STAKEHOLDER INTERVIEWS

“We can support the ecosystem
for their creation by gathering those
who can tangibly foster innovatiovn
and advance product development.”

SPONSOR INTERVIEWS

“The philanthropic, for-profit, and government triad is an extremely valuable partnership that differentiates GHIT from lots of other organizations.”

Dr. Hannah Kettler

Senior Program Officer, Life Science Partnerships
Global Health Program, Office of the President
Bill & Melinda Gates Foundation

STAKEHOLDER INTERVIEWS

“By more directly linking Japanese techniques and craftsmanship to the type of global ideas and concepts embodied by GHIT, I think that we are certain to create great results.”

Mr. George Nakayama

Representative Director, Chairman and CEO
Daiichi Sankyo Company, Limited

STAKEHOLDER INTERVIEWS

“I believe that GHIT has catalyzed
a mindset shift for the Japanese
pharmaceutical industry
vis-à-vis global health R&D.”

Mr. Yoshihiko
Hatanaka

Representative Director,
President and CEO
Astellas Pharma Inc.

STAKEHOLDER
INTERVIEWS

“After all, people cannot address problems of which they are unaware”

SPONSOR INTERVIEWS

“Access to medicine is an issue for everybody, a cross-border issue that goes beyond domestic interests. ”

Dr. Jayasree K. Iyer

Executive Director
Access to Medicine Foundation

STAKEHOLDER INTERVIEWS

“When we all come together and look at the world in a positive way and look at what is possible, we can achieve extraordinary things.”

Dr. Mark Dybul

Former Executive Director
The Global Fund to Fight AIDS,
Tuberculosis and Malaria

STAKEHOLDER INTERVIEWS

“My hope is that some GHIT projects will lead to products that can be provided to patients in endemic regions of infectious diseases.”

Prof. Kiyoshi Kita

Professor Emeritus, The University of Tokyo
Professor and Dean, Nagasaki University School of
Tropical Medicine and Global Health

STAKEHOLDER
INTERVIEWS

“It is a great honor that our technology can help address social problems.”

SPONSOR INTERVIEWS

“I think it is important to create this type of shared value partnership, which will help eliminate as many barriers of entry as possible.”

Dr. Seth Berkley

CEO Gavi, the Vaccine Alliance

STAKEHOLDER INTERVIEWS

“It's very clear that no one can do it alone. You need to have partners”

Dr. Nathalie Strub Wourgaft

Medical Director
Drugs for Neglected Diseases initiative (DNDi)

STAKEHOLDER
INTERVIEWS

“We are clearing the path to promote effective introduction and scale-up of the new health technologies that are emerging from GHIT’s pipeline.”

Mr. Tetsuo Kondo

Director
United Nations Development Programme (UNDP)
Representation Office in Tokyo

STAKEHOLDER INTERVIEWS

“I believe that one of the factors that makes GHIT successful is that it is managed effectively, with strong backing by large pharmaceutical companies, highly reputable foundations, and the Japanese government.”

SPONSOR INTERVIEWS

“I believe that having global public–private partnerships from the very beginning has been a key factor in the GHIT Fund’s success to date.”

Hon. Prof. Keizo Takemi

Member of the House of Councillors of Japan
Chairman, Special Committee on Global Health Strategy
of the Liberal Democratic Party's Policy

STAKEHOLDER INTERVIEWS

“Through GHIT, I believe Japan strengthened its commitment to eradicate, eliminate and control of NTDs for the common goal of a healthier world.”

Dr. Aya Yajima

Technical Officer
Malaria, other Vectorborne and Parasitic Diseases Unit
Division of Communicable Diseases
World Health Organization Western Pacific Regional Office

STAKEHOLDER INTERVIEWS

“GHIT is definitely one of these strategic investments; it delivers an enormous return.”

Prof. Stephen Caddick

Director, Innovations Division,
Wellcome Trus

STAKEHOLDER INTERVIEWS

“GHIT has introduced new values in the global health field and the overall function of public-private partnerships across sectors and borders. This complements our concept of open-minded cities.”

SPONSOR INTERVIEWS

NEWSJourney with us through GHIT’s Past and Future

2017.08.10 NEWS New interview articles have been released
2017.07.13 NEWS New interview articles have been released
2017.06.05 NEWS GHIT Fund 5th Anniversary Film Released
2017.06.01 NEWS New content "GHIT FUTURE" has been added
2017.06.01 NEWS New interview articles have been released
2017.05.10 NEWS New interview articles have been released
2017.04.10 NEW SITE OPEN NEW GHIT Fund 5th Anniversary Website Launched

GHIT FUND HISTORYOur first 5 years (2013-2017)

GHIT FUND FUTUREPlans for the next 5 years (2018-2022)

STAKEHOLDER INTERVIEWSPerspectives from 15 global health leaders on
GHIT's catalytic role and Japan's transformational
contributions to global health R&D

GHIT Fund 5th Anniversary Film

FUNDING

: Dr. Naoko YamamotoSenior Assistant Minister for Global Health
Ministry of Health, Labour and Welfare

: Dr. Hannah KettlerSenior Program Officer, Life Science Partnerships
Global Health Program, Office of the President
Bill & Melinda Gates Foundation

: Prof. Stephen CaddickDirector, Innovations Division
Wellcome Trust

DISCOVERY

: Dr. David ReddyCEO
Medicines for Malaria Venture (MMV)

: Mr. George NakayamaRepresentative Director, Chairman and CEO
Daiichi Sankyo Company, Limited

: Prof. Kiyoshi KitaProfessor Emeritus, The University of Tokyo
Professor and Dean, Nagasaki University School of Tropical Medicine and Global Health

DEVELOPMENT

: Mr. Christophe WeberRepresentative Director, President and CEO
Takeda Pharmaceutical Company Limited

: Mr. Yoshihiko HatanakaRepresentative Director, President and CEO
Astellas Pharma Inc.

: Dr. Nathalie Strub WourgaftMedical Director
Drugs for Neglected Diseases initiative (DNDi)

ACCESS

: Dr. Jayasree K. IyerExecutive Director
Access to Medicine Foundation

: Mr. Tetsuo KondoDirector
United Nations Development Programme (UNDP)
Representation Office in Tokyo

: Dr. Aya YajimaTechnical Officer
Malaria, Other Vectorborne and Parasitic Diseases Unit
Division of Communicable Diseases
World Health Organization Western Pacific Regional Office

POLICY

: Dr. Mark DybulFormer Executive Director
The Global Fund to Fight AIDS, Tuberculosis and Malaria

: Dr. Seth BerkleyCEO
Gavi, the Vaccine Alliance

: Hon. Prof. Keizo TakemiMember of the House of Councillors of Japan
Chairman, Special Committee on Global Health Strategy
of the Liberal Democratic Party's Policy